Loading mutual fund details…
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is an equity scheme managed by Nippon India Mutual Fund. Over rolling three-year windows since inception, investors earned a median compounded return of 20.29%, with the bottom and top quartiles at 17.87% and 22.90% respectively. It has ranked in the top half of its category for 1 of the last 2 reported years. The total expense ratio is 1.48% on assets of ₹8,365Cr. The fund is currently managed by Sailesh Raj Bhan, appointed within the last year.
Lower is better.
This scheme classifies as Large-Blend on the 3x3 equity style box, with 76% of its portfolio classified as of 2026-05-29.
| Holding | Sector |
|---|
| Window | Min | P25 | Median |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Same fund, monthly SIPs over rolling 1/3/5-year windows.
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| Weight |
|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Healthcare | 13.85% |
| LUPIN LIMITED | Healthcare | 7.95% |
| CIPLA LIMITED | Healthcare | 5.47% |
| APOLLO HOSPITALS ENTERPRISE LIMITED | Healthcare | 5.01% |
| MEDPLUS HEALTH SERVICES LIMITED | Consumer Cyclical | 3.78% |
| VIJAYA DIAGNOSTIC CENTRE LIMITED | Healthcare | 3.36% |
| Sai Life Sciences Limited | Healthcare | 3.27% |
| AJANTA PHARMA LIMITED | Healthcare | 3.19% |
| MAX HEALTHCARE INSTITUTE LIMITED | Healthcare | 3.16% |
| MANKIND PHARMA LIMITED | Healthcare | 3.04% |
| AUROBINDO PHARMA LIMITED | Healthcare | 2.83% |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD | Healthcare | 2.55% |
| IPCA LABORATORIES LIMITED | Healthcare | 2.50% |
| ABBOTT INDIA LIMITED | Healthcare | 2.26% |
| THYROCARE TECHNOLOGIES LIMITED | Healthcare | 2.11% |
| ALKEM LABORATORIES LIMITED | Healthcare | 2.09% |
| PFIZER LIMITED | Healthcare | 1.79% |
| NARAYANA HRUDAYALAYA LIMITED | Healthcare | 1.74% |
| GLAND PHARMA LIMITED | Healthcare | 1.68% |
| EMCURE PHARMACEUTICALS LIMITED | Healthcare | 1.50% |
| SYNGENE INTERNATIONAL LIMITED | Healthcare | 1.43% |
| Suraksha Diagnostic Limited | Healthcare | 1.32% |
| SANOFI CONSUMER HEALTHCARE INDIA LIMITED | Healthcare | 1.22% |
| FORTIS HEALTHCARE LIMITED. | Healthcare | 1.22% |
| AKUMS DRUGS AND PHARMACEUTICALS LTD | Healthcare | 0.99% |
| Sector | Holdings | Weight |
|---|---|---|
| Healthcare | 30 | 94.92% |
| Consumer Services | — | 3.78% |
Active bets vs the average Equity fund. Biggest deviations shown first.
Accent bar = fund's actual sector weight. Vertical black tick = category average for the same sector. Green overlay = overweight, dashed red = underweight. The biggest active bets show first.
| P75 |
|---|
| Max |
|---|
| Positive % |
|---|
| 1Y | -14.52% | 0.61% | 16.06% | 38.12% | 65.39% | 76.6% |
| 3Y | 13.98% | 17.87% | 20.29% | 22.90% | 27.82% | 100.0% |
| 5Y | 13.39% | 15.48% | 17.50% | 19.71% | 23.73% | 100.0% |
Each cell is one year. Q1 = top quartile within the AMFI category for that period. Cell label is the last two digits of the year.
Top-10 weight 52.1% means concentration is in line with most actively-managed Indian equity funds. Effective-N is the inverse Herfindahl index — a measure of "how many positions effectively drive the fund" after weighting. Category: Equity.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
What an investor SIPping into this fund actually got during named market shocks.
Each row is a back-tested SIP — monthly contribution over the regime's duration, no fees adjustment beyond NAV-baked TER. XIRR is the annualised IRR of those cashflows; Abs return is the absolute cash-on-cash; Max DD is the deepest drawdown experienced mid-investment. Past performance is not indicative of future results.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.